Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Hidradenitis Suppurativa (HS): New Developments - The Translational Medicine Approach to Pathogenesis and Treatment
Description
The presentation discusses Hidradenitis Suppurativa (HS), emphasizing its complexity and varied pathology across different disease stages (Hurley stages). Unlike psoriasis, HS has inflammation that occurs deeper in the skin, often undetectable at the surface. Advanced imaging techniques reveal inflammatory tunnels filled with neutrophils and unique cytokines implicated in the disease process. The speaker critiques outdated models of HS and introduces updated perspectives on its pathogenesis, incorporating both innate and adaptive immune responses, particularly highlighting the role of IL-17 cytokines. Recent studies show promise for IL-17 antagonists, like secukinumab and bimikizumab, demonstrating significant efficacy in HS treatment, particularly in reducing draining tunnels and inflammatory nodules. Despite the FDA focusing on nodule counts for drug approval, there's a call for more comprehensive metrics that account for the entirety of HS pathology. The discussion also raises the potential role of gram-negative bacteria in exacerbating inflammation in HS, suggesting the need for antibiotic combinations alongside traditional treatments. Overall, the presentation points to an evolving understanding of HS, advocating for targeted therapies informed by ongoing research into its complex immunological and microbial underpinnings.
View moreConclusions
- Hidradenitis suppurativa (HS) is a complex inflammatory disease with distinct stages and underlying pathologies.
- The inflammation in HS is characterized by both visible surface lesions and significant deeper tissue and cytokine involvement.
- Current models of HS must incorporate T-cell dynamics and IL-17 cytokine pathways to accurately reflect disease mechanisms.
- Therapeutics targeting IL-17 cytokines, like secukinumab and bimekizumab, show promising efficacy in treating HS by improving both inflammatory nodules and draining tunnels.
- The relationship between neutrophil activity and the presence of tunnels is crucial in understanding HS pathology and treatment response.
- Objective biomarkers for disease activity in HS are still in development but are critical for effective treatment stratification.
- Combination therapies that include antibiotics may enhance the efficacy of biologics in patients with HS, particularly in those with significant draining tunnels.
- New investigational therapies, such as sonelokimab, offer hope for further advancing treatment options for patients with HS.
- Further research is needed to elucidate the role of specific bacteria in HS pathogenesis and their interaction with immune responses.
- Vossen, van der Zee, Prens. ... Integrating Inflammatory Pathways into a Cohesive Model. Frontiers in Immunology (2018)
- Navrazhina, Frew, Krueger BJD. (2019)
- Wolk, K., Join-Lambert, O. and Sabat, R. (2020). Aetiology and pathogenesis of hidradenitis suppurativa. Br. J. Dermatol., 183: 999-1010. https://doi.org/10.1111/bjd.19556
- Nosrati, A., Ch'en, P. Y., Torpey, M. E., Shokrian, N., Ball, G., Benesh, G., Andriano, T. M., Zhu, T. R., Heibel, H. D., Hosgood, H. D., Campton, K. L., Cohen, S. R. (2024). Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. doi:10.1001/jamadermatol.2023.6201
- Kimball AB et al. N Engl J Med 2016;375:422-34; Kimball AB et al. Lancet 2023;401:747-61; Kimball AB et al. AAD 2023.